NASDAQ:SAVA Cassava Sciences (SAVA) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free SAVA Stock Alerts $20.50 +0.86 (+4.38%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$19.74▼$20.8450-Day Range$18.44▼$26.1152-Week Range$12.32▼$32.10Volume767,487 shsAverage Volume944,738 shsMarket Capitalization$886.63 millionP/E RatioN/ADividend YieldN/APrice Target$124.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Cassava Sciences alerts: Email Address Cassava Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside504.9% Upside$124.00 Price TargetShort InterestBearish27.26% of Shares Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.12Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.01) to $1.67 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.45 out of 5 starsMedical Sector278th out of 910 stocksPharmaceutical Preparations Industry117th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingCassava Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCassava Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted27.26% of the outstanding shares of Cassava Sciences have been sold short.Short Interest Ratio / Days to CoverCassava Sciences has a short interest ratio ("days to cover") of 17, which indicates bearish sentiment.Change versus previous monthShort interest in Cassava Sciences has recently decreased by 1.42%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCassava Sciences does not currently pay a dividend.Dividend GrowthCassava Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCassava Sciences has received a 74.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for Alzheimer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cassava Sciences is -0.82. Previous Next 1.7 News and Social Media Coverage News SentimentCassava Sciences has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Cassava Sciences this week, compared to 5 articles on an average week.Search InterestOnly 30 people have searched for SAVA on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat Follows33 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 106% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cassava Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders12.20% of the stock of Cassava Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 38.05% of the stock of Cassava Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cassava Sciences are expected to grow in the coming year, from ($2.01) to $1.67 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cassava Sciences is -8.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cassava Sciences is -8.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCassava Sciences has a P/B Ratio of 6.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Whats On FinancePutin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. Click to kickstart your journey to survive in the new economy About Cassava Sciences Stock (NASDAQ:SAVA)Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Read More SAVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAVA Stock News HeadlinesApril 21, 2024 | americanbankingnews.comCassava Sciences (NASDAQ:SAVA) Shares Down 6% April 20, 2024 | msn.comHow Western food imports are fuelling obesity in Pacific nationsApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 19, 2024 | finance.yahoo.comCassava Sciences, Inc. (SAVA)April 15, 2024 | globenewswire.comRedemption Date Announced for WarrantsApril 15, 2024 | americanbankingnews.comContrasting Cassava Sciences (NASDAQ:SAVA) & Nabriva Therapeutics (NASDAQ:NBRV)April 14, 2024 | americanbankingnews.comCassava Sciences (NASDAQ:SAVA) Shares Down 9% April 5, 2024 | bizjournals.comAg nonprofit launched by Gates Foundation opens HQ in Cortex, grows to 30 employeesApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 4, 2024 | msn.comStrong quake rocks Taiwan, tsunami warnings issuedApril 3, 2024 | ft.comCan Africa one day help feed the world’s growing population?April 2, 2024 | stockhouse.com24 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CassavaApril 2, 2024 | msn.comTracing science’s transformative impact on manifesto implementationApril 1, 2024 | stockhouse.comFINAL SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Lead the Class Action Lawsuit!March 29, 2024 | prnewswire.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CassavaMarch 29, 2024 | finance.yahoo.comSAVA Apr 2024 17.000 putMarch 28, 2024 | msn.comCassava: How Nutrition Professionals Assess Its Health Benefits, Nutrition Facts, And MoreMarch 28, 2024 | markets.businessinsider.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava SciencesMarch 27, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVAMarch 26, 2024 | au.investing.comCassava Sciences' Alzheimer's drug continues Phase 3 trialsMarch 25, 2024 | seekingalpha.comCassava Sciences: New Year, Same Game Of Smoke And MirrorsMarch 25, 2024 | markets.businessinsider.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CassavaMarch 25, 2024 | globenewswire.comCassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 TrialsMarch 24, 2024 | stockhouse.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CassavaMarch 23, 2024 | stockhouse.comSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the FirmMarch 23, 2024 | markets.businessinsider.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CassavaMarch 21, 2024 | prnewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CassavaSee More Headlines Receive SAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/23/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SAVA CUSIPN/A CIK1069530 Webwww.cassavasciences.com Phone(512) 501-2444Fax512-501-0414Employees29Year FoundedN/APrice Target and Rating Average Stock Price Target$124.00 High Stock Price Target$124.00 Low Stock Price Target$124.00 Potential Upside/Downside+504.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.53% Return on Assets-52.58% Debt Debt-to-Equity RatioN/A Current Ratio9.13 Quick Ratio9.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.26 per share Price / Book6.29Miscellaneous Outstanding Shares43,250,000Free Float37,970,000Market Cap$886.63 million OptionableOptionable Beta-0.45 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Remi Barbier (Age 64)Founder, Chairman, President & CEO Comp: $1.2MMr. Eric J. Schoen (Age 56)Chief Financial Officer Comp: $460kMr. R. Christopher Cook (Age 60)Senior VP, Company Secretary & General Counsel Comp: $425kDr. James W. Kupiec M.D. (Age 71)Chief Medical Officer Comp: $435kDr. George Thornton Ph.D.Senior Vice President of TechnologyMr. Michael ZamlootSenior Vice President of Technical OperationsDr. Michael Marsman Pharm.D.Senior Vice President of Regulatory AffairsDr. Lindsay H. Burns Ph.D.Senior Vice President of NeuroscienceMore ExecutivesKey CompetitorsZentalis PharmaceuticalsNASDAQ:ZNTLInnovivaNASDAQ:INVAABIVAX Société AnonymeNASDAQ:ABVXARS PharmaceuticalsNASDAQ:SPRYSage TherapeuticsNASDAQ:SAGEView All CompetitorsInsiders & InstitutionsPFG Investments LLCBought 21,880 shares on 4/22/2024Ownership: 0.051%Hennion & Walsh Asset Management Inc.Bought 3,151 shares on 4/17/2024Ownership: 0.058%NBC Securities Inc.Bought 650 shares on 4/5/2024Ownership: 0.018%Virtu Financial LLCBought 26,824 shares on 2/26/2024Ownership: 0.116%Cable Car Capital LLCBought 53,500 shares on 2/20/2024Ownership: 0.127%View All Insider TransactionsView All Institutional Transactions SAVA Stock Analysis - Frequently Asked Questions Should I buy or sell Cassava Sciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SAVA shares. View SAVA analyst ratings or view top-rated stocks. What is Cassava Sciences' stock price target for 2024? 1 Wall Street research analysts have issued 1-year price objectives for Cassava Sciences' shares. Their SAVA share price targets range from $124.00 to $124.00. On average, they expect the company's stock price to reach $124.00 in the next year. This suggests a possible upside of 504.9% from the stock's current price. View analysts price targets for SAVA or view top-rated stocks among Wall Street analysts. How have SAVA shares performed in 2024? Cassava Sciences' stock was trading at $22.51 at the start of the year. Since then, SAVA stock has decreased by 8.9% and is now trading at $20.50. View the best growth stocks for 2024 here. When is Cassava Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our SAVA earnings forecast. How were Cassava Sciences' earnings last quarter? Cassava Sciences, Inc. (NASDAQ:SAVA) issued its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.10. What ETFs hold Cassava Sciences' stock? ETFs with the largest weight of Cassava Sciences (NASDAQ:SAVA) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and iShares Neuroscience and Healthcare ETF (IBRN).iShares U.S. Pharmaceuticals ETF (IHE). When did Cassava Sciences' stock split? Cassava Sciences shares split on Thursday, December 21st 2023. The 14-10 split was announced on Thursday, December 21st 2023. The newly issued shares were distributed to shareholders after the market closes on Thursday, December 21st 2023. An investor that had 100 shares of stock prior to the split would have 140 shares after the split. What other stocks do shareholders of Cassava Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA). Who are Cassava Sciences' major shareholders? Cassava Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.06%), PFG Investments LLC (0.05%) and NBC Securities Inc. (0.02%). Insiders that own company stock include Eric Schoen, James William Kupiec, Richard Barry and Sanford Robertson. View institutional ownership trends. How do I buy shares of Cassava Sciences? Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SAVA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
